Efficacy and safety of reslizumab in severe asthma patients with inadequate response to omalizumab: a multicentre, open-label, pilot study

ConclusionReslizumab is an effective and safe option for patients with severe eosinophilic asthma and a history of previous omalizumab failure.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research